Hepa - Merz (Ornithine Aspartate)

Hepa is administered intravenously in a hospital or clinical environment for conditions where modulation of nitrogen metabolism may be beneficial. Typical clinical contexts include:

• Supportive care in patients with acute liver dysfunction
• Adjunct therapy during hepatic encephalopathy management
• Use in postoperative care where liver stress is anticipated
• Investigation in clinical trials evaluating hepatic metabolic support
• Situations requiring rapid correction of plasma amino acid levels

Side effects associated with intravenous ornithine aspartate are generally uncommon but may occur. They are categorized by frequency and severity.

Common

• Mild nausea or vomiting
• Transient headache
• Temporary flushing or warmth at the infusion site
• Mild hypotension during infusion
• Slight increase in serum ammonia levels
• Mild electrolyte disturbances

Serious

• Severe allergic reaction (anaphylaxis)
• Acute respiratory distress
• Significant hypotension requiring intervention
• Persistent elevation of liver enzymes
• Renal impairment in susceptible individuals
• Hemolysis or severe hemolytic anemia

When considering Hepa for intravenous use, clinicians should observe several safety measures:

• Verify patient history for hypersensitivity to ornithine or aspartate compounds.
• Assess liver function tests before and during therapy.
• Monitor blood pressure and vital signs throughout the infusion.
• Use caution in patients with renal insufficiency or electrolyte imbalances.
• Adjust infusion rate if signs of hypotension or discomfort arise.
• Ensure proper aseptic technique to prevent infection at the infusion site.
• Document any adverse reactions promptly for pharmacovigilance.

Intravenous ornithine aspartate may interact with other medications or substances. Interactions are grouped by level of concern.

Avoid

• Concurrent use of high-dose ammonia‑producing agents (e.g., certain chemotherapy drugs).
• Co‑administration with potent vasodilators that may exacerbate hypotension.
• Simultaneous infusion with incompatible solutions (e.g., calcium‑containing fluids).

Use with caution

• Diuretics that affect electrolyte balance.
• Medications metabolized by the liver, such as acetaminophen.
• Anticoagulants, due to potential changes in plasma protein binding.
• Drugs that alter renal clearance, including ACE inhibitors.